Company Overview
Snapshot
Founded in September 2020 by Inna Slutsky and Neta Pessah, Selene Therapeutics operates with 1–10 employees. The company has secured funding across two rounds from three investors. In June 2024, the company received a grant from the Israel Innovation Authority.
Business overview
Selene Therapeutics is a Health Tech & Life Sciences company focused on developing a novel therapeutic strategy for refractory epilepsy. The company's core technology involves small molecules designed as inhibitors of dihydroorotate dehydrogenase, a mitochondrial enzyme. By regulating the neuronal activity set point and reducing the neuronal mean firing rate, Selene Therapeutics aims to address the challenges of epilepsy treatment. The company operates within the Pharmaceuticals sector, specifically in drug development and neurology, and is part of the FuturX biotech incubator.
Log in to access full profile ›Company Intelligence Q&A
- What is Selene Therapeutics' primary focus?
- Selene Therapeutics is developing a new therapeutic strategy for treating refractory epilepsy by regulating the neuronal activity set point through reducing the neuronal mean firing rate.
- What is the company's core technology?
- Selene Therapeutics aims to develop small molecules that act as inhibitors of dihydroorotate dehydrogenase, a mitochondrial enzyme involved in key cellular homeostatic processes.
- When was Selene Therapeutics founded and by whom?
- Selene Therapeutics was founded in September 2020 by Inna Slutsky and Neta Pessah.
- What significant funding did Selene Therapeutics receive in June 2024?
- In June 2024, Selene Therapeutics secured a grant from the Israel Innovation Authority.
- Which investors participated in Selene Therapeutics' Seed round in October 2020?
- In October 2020, Selene Therapeutics received Seed funding from RMGP Biopharma Investment Fund and FutuRx.